Learn more about BRIDION efficacy in special patient populations:
Geriatric patients
Cardiac patients
Pulmonary patients
Recovery in geriatric patients with moderate block
In a dedicated clinical study of geriatric patients (n=102) that compared the time to recovery from rocuronium-induced moderate neuromuscular blockade (NMB), BRIDION demonstrated time to recovery of the train-of-four (TOF) ratio to 0.9 comparable with other treatment groups.
Median time from start of 2 mg/kg of BRIDION to recovery of a TOF ratio of 0.9
|
MINUTES |
Patients 18 to 64 years (n=48) |
|
|
|
MINUTES |
Patients 65 to 74 years (n=62) |
|
|
|
MINUTES |
Patients ≥75 years (n=40) |
|
Study design
Multicenter, parallel-group, open-label study compared the efficacy of 2 mg/kg of BRIDION for reversal of rocuronium-induced moderate NMB (reappearance of T2) in 48 adult patients (18–64 years), 62 geriatric patients (65–74 years), and 40 older geriatric patients (≥75 years) (American Society of Anesthesiologists [ASA] class 1–3). The primary end point was the time from start of BRIDION administration to a TOF ratio (T4/T1) of 0.9.1
Recovery in geriatric patients with deep block
In an analysis of pooled clinical trial data, BRIDION demonstrated rapid reversal of rocuronium-induced deep NMB (TOF count of 0, 1–2 post-tetanic counts [PTCs])2 to recovery of the TOF ratio to 0.9 in geriatric patients.
Median time from start of 4 mg/kg of BRIDION to recovery of a TOF ratio of 0.9
|
MINUTES |
Patients 18 to 64 years (n=359) |
|
|
|
MINUTES |
Patients ≥65 years (n=63) |
|
- No dose adjustment is necessary in geriatric patients with normal organ function.
- Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.
Recovery in cardiac patients with moderate block
In a clinical study, BRIDION provided reversal of rocuronium-induced moderate NMB (reappearance of T2) to recovery of the TOF ratio to 0.9 in patients diagnosed with or having a history of cardiac disease.
Median time from start of BRIDION to recovery of a TOF ratio of 0.9
|
MINUTES |
BRIDION 2 mg/kg |
|
|
|
MINUTES |
BRIDION 4 mg/kg |
|
Study design
Multicenter, randomized, parallel-group, placebo-controlled, safety-assessor–blinded study compared the safety and efficacy of 2 mg/kg and 4 mg/kg of BRIDION for reversal of rocuronium-induced moderate NMB (reappearance of T2) in 76 patients who were diagnosed with or have a history of cardiac disease (eg, patients with ischemic disease, chronic heart failure, or arrhythmia), primarily New York Heart Association (NYHA) Class II. The primary end point was to evaluate the safety of BRIDION 2 mg/kg and 4 mg/kg, with the time from start of BRIDION administration to a TOF ratio of 0.9 as a secondary end point.3
Recovery in pulmonary patients with moderate block
In a clinical study, BRIDION achieved rapid reversal of rocuronium-induced moderate NMB (reappearance of T2) to recovery of the TOF ratio to 0.9 in patients diagnosed with or having a history of pulmonary complications.
Median time from start of BRIDION to recovery of a TOF ratio of 0.9
|
MINUTES |
BRIDION 2 mg/kg |
|
|
|
MINUTES |
BRIDION 4 mg/kg |
|
Study design
Multicenter, randomized, parallel-group, comparative, safety-assessor–blinded study compared the safety and efficacy of 2 mg/kg and 4 mg/kg of BRIDION for reversal of rocuronium-induced moderate NMB (reappearance of T2) in 77 patients who were diagnosed with or have a history of pulmonary complications (ASA class 2 and 3). The primary objective was to evaluate the safety of BRIDION 2 mg/kg and 4 mg/kg, with the time from start of BRIDION administration to a TOF ratio of 0.9 as a primary efficacy objective.4